BEMI PROGRAMS FOR REVESTIVE

beMi Programs for Revestive is a patient support program developed by Takeda to support individuals prescribed Revestive (teduglutide).

Complementing the care provided by each patient’s healthcare team, the program offers nursing support, script management, medical supply delivery, and resources to help patients manage their treatment at home.

beMi Programs for Revestive is available to all patients prescribed Revestive across Australia.

Image

Program overview for Healthcare Professionals

Download to learn how beMi Programs can help you support your patient’s Revestive treatment at home

What services are available?
Program team
Header
Program team
Card Body
A dedicated team of nurses and coordinators to help guide your patient through treatment and coordinator support and services.
Script management
Header
Script management
Card Body
Assistance to help you and your patient manage Revestive prescriptions and renewals.
Medical supply deliveries
Header
Medical supply deliveries
Card Body
Revestive medical supplies are delivered directly to your patient's home every three months.
Resources and tools
Header
Resources and tools
Card Body
Access to resources and tools including the parenteral support diary to help your patient manage their treatment with confidence.

RESOURCES

beMi Programs for Revestive: Participant guide
beMi Programs for Revestive: Participant guide
Information about services and support available through beMi Programs for Revestive, with a stage-by-stage overview of the patient’s treatment journey.
Program enrolment form
Program enrolment form
Interactive PDF to be completed jointly by the treating doctor and patient to enrol the patient in beMi Programs for Revestive.
Care plan for adult patients
Care plan for adult patients
Interactive PDF for HCPs to complete to support documentation and communication of treatment care needs with program nurses.
Care plan for paediatric patients
Care plan for paediatric patients
Interactive PDF for HCPs to complete to support documentation and communication of treatment care needs with program nurses.

PBS Information: This product is listed on the PBS. Authority required. Refer to PBS Schedule for full authority information.

Click here to review full approved Product Information before prescribing.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems